var data={"title":"Japanese encephalitis virus vaccine (inactivated): Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Japanese encephalitis virus vaccine (inactivated): Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6417?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=japanese-encephalitis-virus-vaccine-inactivated-patient-drug-information\" class=\"drug drug_patient\">see &quot;Japanese encephalitis virus vaccine (inactivated): Patient drug information&quot;</a> and <a href=\"topic.htm?path=japanese-encephalitis-virus-vaccine-inactivated-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Japanese encephalitis virus vaccine (inactivated): Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185565\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Ixiaro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13495796\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Ixiaro</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185572\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Vaccine;</li>\n      <li>\n        Vaccine, Inactivated (Viral)</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185567\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Primary immunization:</b> IM: 0.5 mL/dose; a total of 2 doses given on days 0 and 28. Series should be completed at least 1 week prior to potential exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster dose:</b> Booster dose may be given prior to potential re-exposure if the primary series was completed &gt;1 year previously.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> If the second dose is missed, limited data from one clinical trial in adults demonstrate a 99% seroconversion rate when the second dose was administered 11 months after the initial dose.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472151\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=japanese-encephalitis-virus-vaccine-inactivated-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Japanese encephalitis virus vaccine (inactivated): Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Primary immunization:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants and Children 2 months to &lt;3 years: IM: 0.25 mL/dose; a total of 2 doses given on days 0 and 28. Series should be completed at least 1 week prior to potential exposure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;3 years and Adolescent: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Booster dose:</b> Adolescents &ge;17 years: Booster dose may be given prior to potential re-exposure if the primary series was completed &gt;1 year previously. <b>Note:</b> The safety of booster doses in children and adolescents &lt;17 years has not been established.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185568\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160058\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16160059\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185555\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intramuscular [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ixiaro:  (0.5 mL) [latex free; contains albumin bovine, protamine sulfate, sodium metabisulfite]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185543\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25734188\" class=\"block meg drugH1Div\"><span class=\"drugH1\">Medication Guide and/or Vaccine Information Statement (VIS)</span>\n    <p style=\"text-indent:0em;display:inline\">In the U.S, the CDC-approved Vaccine Information Statement (VIS) is available at <a target=\"_blank\" href=\"http://www.cdc.gov/vaccines/hcp/vis/vis-statements/je-ixiaro.html&amp;token=eHT2gIQIJDrUIT/coGlx9gSY7Yyb1totF4b7Kp32W2N3lYPm9JvZ1YLGUBQdrH0HEGIev8kfTnpGiTr4W+k5614BjULpOo0MyH2n4C4zJtg=&amp;TOPIC_ID=8775\" target=\"_blank\">http://www.cdc.gov/vaccines/hcp/vis/vis-statements/je-ixiaro.html</a>.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185558\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;\">IM: For IM injection. Do not inject IV, SubQ, or intradermally. Shake well prior to use to form a homogeneous suspension. Do not use if discolored or if particulate matter remains. Do not mix with other vaccines or injections; separate needles and syringes should be used for each injection (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">When administering to children 2 to 11 months of age, the preferred site for administration is the anterolateral aspect of the thigh; for children 1 to &lt;3 years of age, the anterolateral aspect of the thigh or deltoid muscle may be used (if mass is adequate); the deltoid muscle is the preferred site in children &ge;3 years, adolescents, and adults. To prevent syncope related injuries, adolescents and adults should be vaccinated while seated or lying down (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Ixiaro is available only in a prefilled syringe containing 0.5 mL. In order to administer a 0.25 mL dose in children 2 months to &lt;3 years, first shake the syringe to form a homogenous suspension. Attach a sterile needle to the prefilled syringe and while holding the syringe upright, discard 0.25 mL of the suspension. Attach a new sterile needle prior to administration.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Canadian labeling recommends avoiding IM administration in patients with bleeding disorders (eg, thrombocytopenia, hemophilia) and suggests that SubQ administration may be considered in these patients. Clinical efficacy data regarding this route is lacking and the U.S. labeling does not recommend SubQ administration. For patients at risk of hemorrhage following intramuscular injection, the vaccine should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection. Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (ACIP [Kroger 2017]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185556\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Japanese encephalitis prevention:</b> Active immunization against Japanese encephalitis (JE) for persons 2 months of age and older</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">The Advisory Committee on Immunization Practices (ACIP) recommends vaccination for (CDC [Fischer 2010]; CDC 2013):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Persons spending &ge;1 month in endemic areas during transmission season</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Research laboratory workers who may be exposed to the Japanese encephalitis virus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccination should also be considered for the following:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Travelers to areas with an ongoing outbreak</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Travelers spending &lt;30 days in endemic areas during the transmission season and planning to go outside of urban areas and have an increased risk of exposure. For example, high-risk activities include extensive outdoor activity in rural areas especially at night; extensive outdoor activities such as camping, hiking, etc; staying in accommodations without air conditioning, screens or bed nets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Travelers to endemic areas who are unsure of specific destination, activities, or duration of travel</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Japanese encephalitis vaccine is not recommended for short-term travelers whose visit will be restricted to urban areas or periods outside of the well-defined JE virus transmission season.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185549\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Report allergic or unusual adverse reactions to the Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at <a target=\"_blank\" href=\"https://vaers.hhs.gov/esub/index&amp;token=8m3rK0tzv73hmwLVujPJP0lWL2FxLWQizZTxo5kD83IMEaCGiDnUFaD+0my2cUJQ&amp;TOPIC_ID=8775\" target=\"_blank\">https://vaers.hhs.gov/esub/index</a>.</b> In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Percentage of adverse reactions reported over days 0-56 in adults and 0-7 in pediatric patients. In general, incidence decreased with subsequent dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Central nervous system: Headache (adults 28%; infants, children, and adolescents 2% to 5%), irritability (infants and children &lt;3 years 8% to 15%; children &ge;3 years and adolescents &le;2%), fatigue (adults 11%; infants, children, and adolescents 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Diarrhea (infants and children &lt;3 years 7% to 12%; children &ge;3 years, adolescents, and adults &lt;1% to 2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Tenderness at injection site (adults 36%; children &ge;3 years and adolescents 4% to 10%; infants and children &lt;3 years 3%), pain at injection site (adults 33%; children &ge;3 years and adolescents 6% to 15%; infants and children &lt;3 years 4%), erythema at injection site (infants and children &lt;3 years 6% to 18%; adults 10%; children &ge;3 years and adolescents &le;3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Myalgia (adults 16%; infants, children, and adolescents 2% to 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Flu-like symptoms (adults 12%; infants, children, and adolescents 1% to 8%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Fever (infants and children &lt;3 years 20% to 24%; children &ge;3 years and adolescents 4% to 11%; adults 3%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Skin rash (infants and children &lt;3 years 4% to 8%; children &ge;3 years, adolescents, and adults &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (adults 7%, infants, children, and adolescents &le;2%), vomiting (infants and children &lt;3 years 4% to 8%; children &ge;3 years, adolescents, and adults 1% to 2%), decreased appetite (infants, children, and adolescents 1% to 6%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Infection: Influenza (adults &ge;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Induration at injection site (adults 8%; infants, children, and adolescents &le;1%), swelling at injection site (&le;2% to 4%), itching at injection site (adults 4%; infants, children, and adolescents &le;1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neuromuscular &amp; skeletal: Back pain (adults 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasopharyngitis (adults 5%), pharyngolaryngeal pain (adults 2%), upper respiratory tract infection (adults 2%), sinusitis (adults &ge;1%), cough (adults 1%), rhinitis (adults 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Miscellaneous: Febrile seizures (children &lt;3 years 1%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Appendicitis, cerebral infarction, chest pain, dermatomyositis, disseminated intravascular coagulation, encephalitis, epilepsy, herpes zoster, iritis, labyrinthitis, limb abscess, limb pain, musculoskeletal injury, neuritis, oropharyngeal spasm, ovarian torsion, paresthesia, rectal hemorrhage, rupture of ovarian cyst, seizure, syncope</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185560\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>U.S. labeling:</i> Severe allergic reaction to a previous dose of the vaccine, any other Japanese encephalitis virus vaccine, or any component of the vaccine, including protamine sulfate</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Hypersensitivity to a previous dose of the vaccine or to any component of the formulation; acute severe febrile conditions </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185546\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1 mg/mL) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Syncope: Syncope has been reported with use of injectable vaccines and may result in serious secondary injury (eg, skull fracture, cerebral hemorrhage); typically reported in adolescents and young adults and within 15 minutes after vaccination. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Acute illness: The decision to administer or delay vaccination because of current or recent febrile illness depends on the severity of symptoms and the etiology of the disease. Defer administration in patients with moderate or severe acute illness (with or without fever); vaccination should not be delayed for patients with mild acute illness (with or without fever) (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bleeding disorders: Use with caution in patients with bleeding disorders (including thrombocytopenia); bleeding/hematoma may occur from IM administration; if the patient receives antihemophilia or other similar therapy, IM injection can be scheduled shortly after such therapy is administered (ACIP [Kroger 2017]). Canadian labeling recommends avoiding IM administration in patients with bleeding disorders (eg, thrombocytopenia, hemophilia) and suggests that SubQ administration may be considered in these patients. Clinical efficacy data regarding this route is lacking and the U.S. labeling does not recommend SubQ administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anticoagulant therapy: Use with caution in patients receiving anticoagulant therapy; bleeding/hematoma may occur from IM administration (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration (ie, &gt;1 vaccine on the same day at different anatomic sites) of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Altered immunocompetence: Consider deferring immunization during periods of severe immunosuppression (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines. Inactivated vaccines should be administered &ge;2 weeks prior to planned immunosuppression when feasible; inactivated vaccines administered during chemotherapy should be readministered after immune competence is regained (ACIP [Kroger 2017]; Rubin 2014).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Pediatric: Apnea has occurred following intramuscular vaccine administration in premature infants; consider clinical status implications. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (ACIP [Kroger 2017]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Protamine sulfate: May contain protamine sulfate which may cause hypersensitivity reactions in certain individuals.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antipyretics: Antipyretics have not been shown to prevent febrile seizures; antipyretics may be used to treat fever or discomfort following vaccination (ACIP [Kroger 2017]). One study reported that routine prophylactic administration of acetaminophen prior to vaccination to prevent fever decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Because of the potential for severe adverse reactions, not recommended for all persons traveling to or residing in Asia. Use is not recommended for short term travelers (&lt;30 days) who will not be outside of an urban area or when the visit is outside of a well-defined Japanese encephalitis virus transmission season. Risk of exposure to the Japanese encephalitis virus may vary from year to year for a particular area. Immunization should be completed &ge;7 days prior to potential exposure (CDC [Fischer 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (ACIP [Kroger 2011]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Other methods to reduce mosquito exposure: Use of vaccine should also include other means to reduce the risk of mosquito exposure (bed nets, insect repellents, protective clothing, avoidance of travel in endemic areas, and avoidance of outdoor activity during twilight and evening periods) (CDC [Fischer 2010]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299552\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185550\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8775&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Patients should receive inactivated vaccines prior to initiation of belimumab therapy whenever possible, due to the risk for an impaired response to the vaccine during belimumab therapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting fingolimod. If vaccinated during fingolimod therapy, revaccinate 2 to 3 months after fingolimod discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated). Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<b> Exceptions: </b>Cytarabine (Liposomal).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Venetoclax: May diminish the therapeutic effect of Vaccines (Inactivated).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F185552\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F4104746\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Risks of vaccine administration should be carefully considered and in general, pregnant women should only be vaccinated if they are at high risk for exposure. Infection from Japanese encephalitis during the first or second trimesters of pregnancy may increase risk of miscarriage. Intrauterine transmission of the Japanese encephalitis virus has been reported (CDC [Fischer 2010]). To report inadvertent use of Ixiaro during pregnancy, contact Intercell USA (844-349-4276).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10096246\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if the vaccine is excreted into breast milk; however, the ACIP does not consider breastfeeding to be a contraindication (CDC [Fischer 2010]). The manufacturer recommends that caution be used if administered to breastfeeding women.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7676566\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Observe for anaphylaxis and syncope for 15 minutes following administration (ACIP [Kroger 2017]). If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472071\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">This vaccine induces antibodies to neutralize the Japanese encephalitis virus. Antibody response is measured using a 50% plaque-reduction neutralization antibody test (PRNT<sub>50</sub>); a threshold of &ge;1:10 is considered protective immunity.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20472073\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset: Protective immunity was observed in ~21% of adults 10 days after the first vaccine dose and in 96% to 100% of children and adults 28 days after the second vaccine dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Protective immunity was observed in ~80% to 85% of adults 12-36 months after the initiation of the two-dose series.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038664\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Ixiaro (AT, CZ, DE, DK, EE, ES, FR, GB, HK, HR, HU, IE, LT, LU, NL, NO, PL, PT, SE, SG, SK);</li>\n      <li>Jebix V (JP);</li>\n      <li>Jencevac (IN);</li>\n      <li>Jespect (AU)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Use of Japanese encephalitis vaccine in children: recommendations of the advisory committee on immunization practices, 2013. <i>MMWR Morb Mortal Wkly Rep</i>. 2013;62(45):898-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/24226626/pubmed\" target=\"_blank\" id=\"24226626\">24226626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control and Prevention (CDC). Recommendations for Use of a Booster Dose of Inactivated Vero Cell Culture-Derived Japanese Encephalitis Vaccine -- Advisory Committee on Immunization Practices, 2011,&quot; <i>MMWR Morb Mortal Wkly Rep</i>, 2011, 60(20):661-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/21617632/pubmed\" target=\"_blank\" id=\"21617632\">21617632</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Fischer M, Lindsey N, Staples JE, et.al. Centers for Disease Control and Prevention (CDC), &ldquo;Japanese Encephalitis Vaccines. Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo; <i>MMWR Recomm Rep</i>, 2010, 59(RR-1):1-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/20224546/pubmed\" target=\"_blank\" id=\"20224546\">20224546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ixiaro (Japanese encephalitis vaccine, inactivated, adsorbed) [prescribing information]. Gaithersburg, MD: Intercell USA, Inc; March 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ixiaro (Japanese encephalitis vaccine, inactivated, adsorbed) [product monograph]. Vienna, Austria; Valneva Austria GMBH; March 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &ldquo;Japanese Encephalitis Vaccines,&rdquo; <i>Wkly Epidemiol Rec</i>, 2006, 81(34/35):331-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/16933380/pubmed\" target=\"_blank\" id=\"16933380\">16933380</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kroger AT, Duchin J, Vazquez M. General Best Practice Guidelines for Immunization. Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP). <a href=\"https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf\" target=\"_blank\">https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/downloads/general-recs.pdf</a>. Accessed April 4, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo; <i>Lancet</i>, 2009, 374(9698):1339-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/19837254/pubmed\" target=\"_blank\" id=\"19837254\">19837254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. <i>Clin Infect Dis</i>. 2014;58(3):e44-e100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/24311479/pubmed\" target=\"_blank\" id=\"24311479\">24311479</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Schuller E, Jilma B, Voicu V, et al, &ldquo;Long-Term Immunogenicity of the New Vero Cell-Derived, Inactivated Japanese Encephalitis Virus Vaccine IC51 Six and 12 Month Results of a Multicenter Follow-up Phase 3 Study,&rdquo; <i>Vaccine,</i> 2008, 26(34):4382-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/18599165/pubmed\" target=\"_blank\" id=\"18599165\">18599165</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tauber E, Kollaritsch H, von Sonnenburg F, et al, &ldquo;Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of the Safety and Tolerability of IC51, an Inactivated Japanese Encephalitis Vaccine,&rdquo; <i>J Infect Dis</i>, 2008, 198(4):493-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/18588481/pubmed\" target=\"_blank\" id=\"18588481\">18588481</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tauber E, Kollaritsch H, Korinek M, et al, &ldquo;Safety and Immunogenicity of a Vero-Cell-Derived, Inactivated Japanese Encephalitis Vaccine: A Non-Inferiority, Phase III, Randomised Controlled Trial,&rdquo; <i>Lancet</i>, 2007, 370(9602):1847-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/japanese-encephalitis-virus-vaccine-inactivated-drug-information/abstract-text/18061060/pubmed\" target=\"_blank\" id=\"18061060\">18061060</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8775 Version 112.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F185565\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F13495796\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F185572\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F185567\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F20472151\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F185568\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F16160058\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F16160059\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F185555\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F185543\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Medication Guide and/or Vaccine Information Statement (VIS)\" href=\"#F25734188\" class=\"outlineLink\">Medication Guide and/or Vaccine Information Statement (VIS)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F185558\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F185556\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F185549\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F185560\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F185546\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299552\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F185550\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F185552\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F4104746\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10096246\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F7676566\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20472071\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20472073\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038664\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8775|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=japanese-encephalitis-virus-vaccine-inactivated-patient-drug-information\" class=\"drug drug_patient\">Japanese encephalitis virus vaccine (inactivated): Patient drug information</a></li><li><a href=\"topic.htm?path=japanese-encephalitis-virus-vaccine-inactivated-pediatric-drug-information\" class=\"drug drug_pediatric\">Japanese encephalitis virus vaccine (inactivated): Pediatric drug information</a></li></ul></div></div>","javascript":null}